| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
68,492,000 |
| Market
Cap: |
3.73(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$31.71 - $59.76 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 446 |
| Guru Rank Value : 4.5 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Protagonist Therapeutics is a clinical-stage biopharmaceutical company with various peptide-based new chemical entities in different stages of development, all derived from Co.'s proprietary technology platform. Co.'s clinical programs address two main categories of diseases; hematology and blood disorders, and inflammatory and immunomodulatory diseases. Co.'s main clinical asset, rusfertide (generic name for PTG-300) is an injectable hepcidin mimetic in development for the potential treatment of erythrocytosis, iron overload and other blood disorders. PN-943 is an investigational, orally delivered, gut-restricted alpha-4-beta-7 specific integrin antagonist for inflammatory bowel disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
21,756 |
38,673 |
324,939 |
543,183 |
| Total Sell Value |
$1,206,176 |
$1,627,783 |
$14,748,344 |
$20,779,345 |
| Total People Sold |
2 |
4 |
5 |
5 |
| Total Sell Transactions |
3 |
7 |
17 |
28 |
| End Date |
2025-03-27 |
2024-12-24 |
2024-06-25 |
2023-06-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Patel Dinesh V Ph D |
President and CEO |
• • – |
2025-06-16 |
4 |
GD |
$0.00 |
$0 |
D/D |
685 |
562,905 |
|
- |
|
| Patel Dinesh V Ph D |
President and CEO |
• • – |
2025-06-13 |
4 |
GD |
$0.00 |
$0 |
D/D |
670 |
563,590 |
|
- |
|
| Molina Arturo Md |
Chief Medical Officer |
• – – |
2025-06-10 |
4 |
S |
$57.03 |
$570,300 |
D/D |
(10,000) |
83,892 |
|
5% |
|
| Molina Arturo Md |
Chief Medical Officer |
• – – |
2025-06-10 |
4 |
OE |
$8.04 |
$80,400 |
D/D |
10,000 |
93,892 |
|
- |
|
| Molina Arturo Md |
Chief Medical Officer |
• – – |
2025-06-09 |
4 |
S |
$55.51 |
$555,100 |
D/D |
(10,000) |
83,892 |
|
4% |
|
| Molina Arturo Md |
Chief Medical Officer |
• – – |
2025-06-09 |
4 |
OE |
$8.04 |
$80,400 |
D/D |
10,000 |
93,892 |
|
- |
|
| Selick Harold E |
Director |
– • – |
2025-04-28 |
4 |
OE |
$1.16 |
$12,441 |
D/D |
10,725 |
43,851 |
|
- |
|
| Ali Asif |
Chief Financial Officer |
• – – |
2025-04-22 |
4 |
S |
$46.00 |
$80,776 |
D/D |
(1,756) |
61,065 |
|
-17% |
|
| Waddill William D. |
Director |
– • – |
2025-03-17 |
4 |
AS |
$54.25 |
$217,000 |
D/D |
(4,000) |
13,130 |
|
1% |
|
| Patel Dinesh V Ph D |
President and CEO |
• • – |
2025-03-05 |
4 |
OE |
$4.21 |
$101,040 |
D/D |
24,000 |
564,260 |
|
- |
|
| Patel Dinesh V Ph D |
President and CEO |
• • – |
2025-02-19 |
4 |
S |
$38.18 |
$204,607 |
D/D |
(5,359) |
540,260 |
|
-39% |
|
| Molina Arturo Md |
Chief Medical Officer |
• – – |
2025-01-16 |
4 |
S |
$0.00 |
$0 |
D/D |
(3,640) |
83,892 |
|
-25% |
|
| Ali Asif |
Chief Financial Officer |
• – – |
2025-01-16 |
4 |
S |
$0.00 |
$0 |
D/D |
(3,918) |
62,821 |
|
-25% |
|
| Patel Dinesh V Ph D |
President and CEO |
• • – |
2025-01-15 |
4 |
D |
$0.00 |
$0 |
D/D |
(12,636) |
545,619 |
|
- |
|
| Odowd Sarah A |
Director |
– • – |
2025-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
5,130 |
5,130 |
|
- |
|
| Molina Arturo Md |
Chief Medical Officer |
• – – |
2025-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
41,088 |
87,532 |
|
- |
|
| Williams Lewis T |
Director |
– • – |
2025-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
5,130 |
5,130 |
|
- |
|
| Waddill William D. |
Director |
– • – |
2025-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
5,130 |
17,130 |
|
- |
|
| Selick Harold E |
Director |
– • – |
2025-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
5,130 |
33,126 |
|
- |
|
| Giraudo Bryan |
Director |
– • – |
2025-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
5,130 |
15,130 |
|
- |
|
| Patel Dinesh V Ph D |
President and CEO |
• • – |
2025-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
149,800 |
558,255 |
|
- |
|
| Ali Asif |
Chief Financial Officer |
• – – |
2025-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
31,779 |
66,739 |
|
- |
|
| Molina Arturo Md |
Chief Medical Officer |
• – – |
2024-11-27 |
4 |
S |
$44.50 |
$1,162,280 |
D/D |
(26,000) |
46,444 |
|
9% |
|
| Molina Arturo Md |
Chief Medical Officer |
• – – |
2024-11-27 |
4 |
OE |
$8.04 |
$209,040 |
D/D |
26,000 |
62,444 |
|
- |
|
| Gupta Suneel |
Chief Development Officer |
• – – |
2024-11-26 |
4 |
OE |
$12.17 |
$370,577 |
D/D |
30,450 |
267,433 |
|
- |
|
212 Records found
|
|
Page 1 of 9 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.76 (1.42%) 
